Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201
Tumor Immunotherapy01:27

Tumor Immunotherapy

575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

12
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
12
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

13
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
13
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

16
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
16

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

HSCT in SAVI: evidence for a curative hematopoietic approach and perspectives for gene therapy.

Molecular therapy. Advances·2026
Same author

Anifrolumab, a potential treatment for ADA2 deficiency.

RMD open·2026
Same author

SARS-CoV-2 Reinfection and Risk of Multisystem Inflammatory Syndrome in Children: A Case-Control Study.

The Pediatric infectious disease journal·2026
Same author

Further detail required to assess additional evidence on agreement between VITEK 2 and broth microdilution piperacillin/tazobactam testing in cephalosporin resistant Enterobacterales.

Journal of clinical microbiology·2026
Same author

Belimumab use in paediatric-onset systemic lupus erythematosus: a status report in France from a retrospective multicentre descriptive study.

Rheumatology (Oxford, England)·2026
Same author

Single-cell analysis identifies CPT1a-associated metabolic remodeling in human NK cells during COVID-19.

Journal of immunology (Baltimore, Md. : 1950)·2026

相关实验视频

Updated: Jul 25, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

1.8K

针对MIS-C的免疫调节疗法

Naïm Ouldali1,2,3, Mary Beth F Son4,5, Andrew J McArdle6

  • 1Division of Infectious diseases, Department of Pediatric Infectious Diseases, Sainte Justine University Hospital, University of Montreal, Quebec, Canada.

Pediatrics
|June 28, 2023
PubMed
概括
此摘要是机器生成的。

与IVIG单独相比,静脉注射免疫球蛋白 (IVIG) 和葡萄糖皮质激素的组合改善了多系统炎症综合征 (MIS-C) 的儿童的心血管功能障碍. 单独使用葡萄糖皮质类药物并没有显示出改善的结果.

更多相关视频

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

450
Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C
07:13

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C

Published on: March 25, 2016

18.5K

相关实验视频

Last Updated: Jul 25, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

1.8K
Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

450
Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C
07:13

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C

Published on: March 25, 2016

18.5K

科学领域:

  • 儿科重症监护医药 儿科重症监护医药
  • 免疫学 免疫学 免疫学
  • 传染病 传染病 传染病

背景情况:

  • 儿童多系统炎症综合征 (MIS-C) 治疗策略有相互矛盾的证据.
  • 对MIS-C的最佳初始治疗仍然是积极研究的领域.

研究的目的:

  • 为了比较静脉注射免疫球蛋白 (IVIG),葡萄糖皮质类药物或它们的组合作为MIS-C的初始治疗的有效性.
  • 评估不同治疗方案对MIS-C患者心血管功能障碍的影响.

主要方法:

  • 随机和观察性比较研究的系统审查和元分析.
  • 在2020年1月至2022年2月期间搜索了Medline,Embase,CENTRAL和WOS.
  • 包括21岁以下的MIS-C患者;使用倾向性得分匹配分析分析了心血管功能障碍.

主要成果:

  • 对来自3个非随机队列的958名儿童的分析显示,IVIG加上葡萄皮质类药物改善了心血管功能障碍 (CD),与单独使用IVIG相比 (OR 0.62).
  • 单独使用葡萄皮质固醇与单独使用IVIG (OR 0.57) 或IVIG加葡萄皮质固醇 (OR 0.67) 相比,并没有改善CD.
  • 二次分析表明,IVIG加上葡萄皮糖类药物对发烧持续时间和二次治疗的需要有好处.

结论:

  • 与IVIG单独治疗相比,IVIG和葡萄糖皮质激素的组合证明了MIS-C患者心血管结果的改善.
  • 作为MIS-C的唯一初始治疗方法的葡萄糖皮质类药物没有显示出优越的心血管益处.
  • 包含的研究的非随机性质是一个关键的限制.